GR-205171 (Glaxo Wellcome plc). 
Glaxo Wellcome is developing the NK1 antagonist GR-205171 for the potential treatment of chemotherapy- and radiotherapy-induced emesis, post-operative nausea and emesis, and migraine.  Phase II trials have commenced for both these indications.  GR-205171 has a similar affinity for the NK1 receptor as CP-99994 [176071,193105].  Glaxo anticipates NDA and MAA filings in 2000 [244813].  A trial of GR-205171 in combination with ondansetron demonstrated the combination to be highly effective in the prevention of acute cisplatin-induced emesis.  Complete responses were seen in all patients receiving high-dose GR-205171 plus ondansetron.  The combination provided complete control of nausea in 16 h in 10 out of 12 patients [289484].  The compound has an ED90 value of 0.03 mg/kg against radiation-induced emesis in the ferret [207316].  GR-205171 is also active against adjuvant-induced inflammatory pain in the rat and may be of potential use in the treatment of chronic inflammatory pain.